CGC:NSD-Canopy Growth Corporation (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 33.39

Change

-1.23 (-3.55)%

Market Cap

USD 12.91B

Volume

7.77M

Average Target Price

USD 27.78 (-16.82%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis for recreational and medical purposes primarily in Canada, the United States, Germany, and the United Kingdom. It operates through two segments, Cannabis, Hemp and Other Consumer Products; and Canopy Rivers. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. As of February 14, 2020, it operated 28 cannabis retail stores under the Tweed or Tokyo Smoke name. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-15 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CRON Cronos Group Inc

-0.33 (-2.93%)

USD4.01B 39.23 N/A
APHA Aphria Inc

+0.31 (+2.56%)

USD3.50B 40.50 454.68
PCRX Pacira BioSciences, Inc

-3.48 (-4.51%)

USD3.35B 26.33 65.69
TLRY Tilray, Inc

+1.14 (+6.14%)

USD2.94B N/A N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.30 (-2.65%)

USD1.81B 16.21 14.06
ENDP Endo International plc

-0.10 (-1.39%)

USD1.66B N/A 9.98
SUPN Supernus Pharmaceuticals, Inc

+0.43 (+1.49%)

USD1.52B 11.94 7.22
ORGO Organogenesis Holdings Inc

+0.01 (+0.11%)

USD1.21B 456.50 77.95

ETFs Containing CGC

Symbol Name Weight Mer Price(Change) Market Cap
CROP IQ Global Agribusiness Sm.. 0.00 % 0.76 %

N/A

USD6.04M
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

-0.11 (-0.55%)

USD0.94B
CNBS Amplify Seymour Cannabis .. 0.00 % 0.75 %

-0.27 (-1.13%)

N/A
THCX The Cannabis ETF 0.00 % 0.70 %

-0.09 (-0.50%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.51% 77% C+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.51% 77% C+ 93% A
Trailing 12 Months  
Capital Gain 34.15% 84% B 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.15% 84% B 70% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -16.88% 33% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.88% 33% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 33.35% 65% D 43% F
Risk Adjusted Return -50.61% 30% F 12% F
Market Capitalization 12.91B 100% A+ 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.95 59% F 48% F
Price / Cash Flow Ratio -16.71 88% B+ 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -30.83% 57% F 30% F
Return on Invested Capital -22.65% 54% F 28% F
Return on Assets -6.85% 58% F 30% F
Debt to Equity Ratio 9.11% 61% D- 76% C
Technical Ratios  
Short Ratio 7.69 32% F 14% F
Short Percent 35.67% 2% F 6% F
Beta 2.33 13% F 9% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector